Tierra Biosciences Alternatives for Transparent CFPS Reagents

Researchers comparing cell-free protein synthesis (CFPS) options against Tierra Biosciences are usually asking the wrong question, because Tierra solves a different problem than the one most in-house labs have. Tierra, founded in 2015 as Synvitrobio by Zachary Sun, George Church, and Richard Murray, produces designer proteins to order using cell-free machinery drawn from microbial cells such as E. coli among other systems spanning diverse organisms, and it accepts large volumes of digital protein sequences through an online portal with AI-assisted sequence analysis ahead of synthesis and QC. Material Impact led Tierra's March 2024 Series A of $11.4M, confirming that Tierra is built to scale as a fulfillment service rather than a reagent supplier. That structure leaves a real gap for researchers who need to run CFPS themselves, whether for iterative variant screening, integration with lab automation, or keeping proprietary sequences off a third party's servers, since none of these needs are compatible with sending sequences out and waiting for protein to come back. None of this reflects poorly on what Tierra delivers as a service. It's a mismatch of category: the audience this piece addresses needs reagents it can run, adapt, and audit on its own bench. What that audience actually needs, concretely, is documented formulations, lot-level QC data, and a pricing structure that makes running hundreds or thousands of reactions financially sane.

Reagent system requirements before transparency or cost

CFPS works because it keeps a cell's own agenda, growth and reproduction, separate from the researcher's agenda, which is to make protein and purify it with minimal fuss. That separation lets the platform handle proteins that would kill a living cell or simply refuse to fold inside one: toxic, unstable, or structurally complex targets that cell-viability constraints would otherwise rule out.

Two architectures dominate the field, and they sit at opposite ends of a spectrum between yield and control. Crude lysate systems, drawn from E. coli, rabbit reticulocyte, wheat germ, insect cells, or human cells, tend to produce more protein per reaction at lower cost, but their exact composition is only partially known and varies somewhat from batch to batch. The PURE system takes the opposite approach: individually purified ribosomes, tRNAs, translation factors, and RNA polymerase give a researcher precise knowledge of what's in the tube, along with reduced background activity and better stability, at the highest per-reaction cost in the field.

Growth media and cell density during culturing measurably affect how fast and how much protein a lysate-based system produces, so batch-to-batch variability is built into these systems at the biological level. A supplier choosing not to disclose that variability doesn't make it go away. It only makes it harder for a researcher to tell whether a failed reaction is a real biological problem or an artifact of an undocumented batch.

The same openness that makes lysate systems variable also makes CFPS unusually capable of handling things a living cell can't easily accommodate: unnatural amino acids, cofactors, lipid mimetics for membrane proteins, accessory enzymes for post-translational modification. But you can only use that flexibility if you first know what's already in the reaction before you add anything to it. Reagent suppliers focused on in-house CFPS work, including Sepia Bio, address this by publishing formulations openly, so researchers can control additions and optimize conditions for difficult proteins instead of guessing at what's already present.

The four criteria that differentiate in-house CFPS reagents from one another

Four criteria separate one in-house CFPS reagent system from another, and they matter in a specific order because each one depends on the one before it.

Formulation transparency comes first. If you want to troubleshoot a failed reaction at all, you need the reaction components, concentrations, and buffer composition documented and public. Conventional CFPS systems often withhold individual component details, which limits a researcher's ability to optimize expression conditions. This opacity is not neutral: it actively blocks diagnosis and improvement.

Lot-level QC data comes second, but you need transparency first, so you have something to interpret it against. A supplier's publication of functional performance data, yield, activity, background, for each lot lets a researcher catch a failed batch before it ruins weeks of screening. This isn't a courtesy. Extract preparation variables, including growth media, cell density, and lysis method, produce genuine performance differences between lots, so the data has a mechanistic basis rather than being a marketing add-on.

Pricing structure relative to throughput comes third. Reagent costs make up roughly three-quarters of all material costs in cell-free expression, so when the per-reaction price is high, you don't just pay more, you lose high-throughput screening as an option. If a supplier prices per reaction, per milliliter, or in volume tiers, that choice decides whether a lab can afford to screen a large variant library.

Automation and format compatibility comes fourth. A reagent that performs reliably in 96- or 384-well plate formats, at the small volumes liquid-handling robots dispense, exemplifies automation and format compatibility. A reagent that doesn't forces manual workarounds, and manual workarounds reintroduce the very variability the first two criteria were meant to catch.

The order is the argument. Transparency is what makes the other three criteria legible at all: QC data means little if you don't know what's being measured against, pricing claims mean little if you can't verify what's driving the cost, and automation compatibility means little if the reagent's behavior under automation can't be traced back to a known formulation.

Reagent cost structure and the rise of high-throughput CFPS

High reagent cost has been the main engineering barrier keeping CFPS out of high-throughput workflows, and the past two years of published work suggest that barrier was never inherent to the chemistry. A 2026 Nature Communications study reported an optimized formulation that cost 99% less than the long-standing PANOx-SP system, and it also cost substantially less than the previous lowest-cost system on record. So when a lab treats formulation as something to engineer deliberately, rather than a fixed recipe to accept as given, it can get high yield and low cost at the same time.

The practical implication for anyone evaluating a commercial reagent is direct: a supplier that won't publish its formulation can't credibly claim its price reflects genuine cost optimization rather than margin protection. Transparency and affordability turn out to be linked rather than separate questions, because the only way to verify that a low price comes from efficient engineering, rather than corner-cutting, is to see what's actually in the formulation.

The PURE system illustrates the trade-off at the opposite extreme. You get the highest compositional transparency available, built from individually purified components, but you pay the highest per-reaction cost in the field for it. At that per-reaction cost, PURE isn't a good primary reagent for large-scale variant screening even if transparency matters most to you. The lesson from the 2026 Nature Communications result is that this trade-off is a consequence of which formulation a given system has chosen to build around, not a law of nature, and other systems have since shown that transparency and low cost can coexist in the same reagent.

Because reagent costs make up roughly three-quarters of material costs in cell-free expression, pricing structure has a direct effect on how much screening a lab can actually run. Per-reaction pricing built to scale with high-throughput screening is what unlocks CFPS's real advantage over cell-based expression, and systems engineered from the outset for cost-competitive, throughput-friendly workflows, priced so that large variant library screening is financially realistic rather than a special case, are the ones that make that advantage usable in practice.

Scoring the available in-house CFPS options across the four criteria

So when you ask which in-house CFPS reagent offers the best cost per milligram for high-throughput campaigns, or which system handles multiple template formats without sacrificing the ability to make complex proteins, what you're really asking is how each available option scores against the four criteria above. Here is how the current landscape breaks down.

The PURE system, fully reconstituted from individually purified components, offers the field's highest pricing transparency: every ribosome, tRNA, translation factor, and RNA polymerase is purified and known, which is also why its per-reaction cost makes large-scale screening prohibitive. Lot-to-lot consistency is strong, because defined components behave more predictably than crude extract, but you can't move the cost ceiling without switching to a different system architecture. PURE fits fundamental mechanistic work where knowing what's in the reaction outweighs the need to run thousands of wells.

Wheat germ extract and other plant-based systems deliver high protein yield, handle complex proteins well, produce soluble protein, and translate independently of a cap structure; tobacco BY-2 extract in particular achieves higher protein levels than commercial wheat germ extract in both batch and dialysis formats. The constraint is batch consistency: lysate preparation is labor-intensive, and that labor doesn't guarantee the same performance run to run, which limits these systems in bulk biomanufacturing settings where reproducibility across runs is the whole point. They still work well for eukaryotic targets where post-translational context matters, but you can't push them to real screening scale.

Labs that build this kind of extract in-house get full compositional transparency, but only by investing in the process itself. That's a legitimate path for a well-resourced group with extract-preparation expertise already on staff, not a reagent a lab can simply order and open. The extract can also be lyophilized without losing its ability to synthesize protein, which helps with storage and shipping logistics.

Open-source endogenous E. coli TX-TL systems push cost efficiency furthest. One published preparation makes as much protein as T7-based systems at a very large cost reduction relative to comparable commercial systems, and a more recent academic platform reports comparable yields at nearly 97.5% lower cost than commercial alternatives. The trade-off is that these aren't commercial reagents. A lab adopting one has to build out extract preparation, standardization, and internal QC from scratch, and that expertise and time investment can exceed the savings for a smaller team.

Sino Biological's cell-free expression service platform follows the same model as Tierra: it's a service, not a reagent a lab runs itself. If you need control over reaction conditions, access to the underlying formulation, or the ability to run iterative screens in-house, you will hit the same category mismatch again.

Sepia Biosciences' OpenCFPS platform is built for two specific jobs: rapid screening across large protein variant libraries, and milligram-scale production once a candidate is chosen, with pricing designed to make high-throughput work the normal case rather than an expensive exception. Formulations are documented and public, and you get lot-level QC data published per lot, so you can trace a bad run back to a specific batch instead of writing it off as noise. The system is built to run in standard 96- and 384-well formats on standard liquid-handling automation and ordinary incubators, so it fits into infrastructure a lab already has rather than demanding new equipment. For researchers working with difficult proteins, toxic, unstable, insoluble, or made of multiple domains, the combination of an open reaction environment and documented composition means cofactors, unnatural amino acids, or accessory enzymes can be added with confidence about what the baseline reaction already contains.

When the protein target itself should drive system selection

Picking a CFPS system isn't only a matter of reagent quality. The protein itself can rule certain architectures in or out before you even get to pricing or transparency.

Toxic or unstable proteins are where CFPS has a structural advantage over any cell-based system, because there's no cell viability to protect in the first place. The system's openness is the actual reason CFPS works where a living-cell expression system fails.

Membrane proteins pose a different challenge: you have to test multiple membrane-mimetic conditions rather than pick one and hope. A high-throughput screen across 61 eukaryotic membrane protein targets, tested across detergents, liposomes, and nanodiscs, found that 57% of all tested targets could be expressed in soluble form in at least one mimetic condition, with detergents outperforming both nanodiscs and liposomes. CFPS suits this kind of screening well, but only if the researcher can test several mimetic conditions efficiently, and that in turn depends on knowing what the baseline formulation contains before adding a detergent or lipid system on top of it.

Proteins that require post-translational modification, disulfide bonds or glycosylation among them, call for a eukaryotic chassis such as yeast (Saccharomyces cerevisiae) or insect cell extract (Spodoptera frugiperda, often referred to as Sf21). No amount of transparency or cost advantage in an E. coli-based lysate changes this. The chassis has to match the biology the target protein needs, and that constraint outranks every criterion this piece has discussed so far.

For large variant libraries and iterative screening campaigns, what decides the outcome is whether the reagent's format and pricing can actually support the automation you want to run. CFPS's open reaction environment and reproducibility let it work with liquid-handling robots and digital microfluidics that can run thousands of parallel reactions, but you only get usable screening capacity from that if the reagent's pricing and plate-format performance are built to support it at that scale.